SGC-CBP30|cas:1613695-14-9|西域试剂

SGC-CBP30,99.60%

产品编号：Bellancom-15826| CAS NO：1613695-14-9| 分子式：C₂₈H₃₃ClN₄O₃| 分子量：509.04

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-15826	￥837.00	杭州北京（现货）
Bellancom-15826	￥1256.00	杭州北京（现货）
Bellancom-15826	￥1469.00	杭州北京（现货）
Bellancom-15826	￥4985.00	杭州北京（现货）
Bellancom-15826	￥9650.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SGC-CBP30

产品介绍

SGC-CBP30 是一种有效且高度选择性的 CBP/p300 溴结构域抑制剂 (对 CBP 和 p300 的 K_d 值分别为 21 nM 和 32 nM)，其选择性是 BRD4 [BRD4(1)] 的 40 倍。SGC-CBP30 强烈减少 Th17 细胞中 IL-17A 的分泌，并具有抗炎作用。

生物活性

SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects.

体外研究

In ankylosing spondylitis and psoriatic arthritis condition, SGC-CBP30 inhibits IL-17A secretion by Th17 cells. Transcriptional profiling of human T cells after SGC-CBP30 treatment shows a much more restricted effect on gene expression than that observed with the pan-BET (bromo and extraterminal domain protein family) bromodomain inhibitor JQ1.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

SGC-CBP30 treatment slightly alleviates alveolar bronchial fibrosis induced by NSC-125066. SGC-CBP30 plus CQ-061 dramatically reduces alveolar bronchial fibrosis. The ELISA of cytokines IL-4 and IFN-γ in BALF demonstrates that combination of SGC-CBP300 and CQ-061 suppresses the activation of IL-4 as well as IFN-γ in NSC-125066 induced IPF murine models to nearly normal levels.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley (SD) rats (aged 3-4 weeks) injected with NSC-125066
Dosage:	25 mg/kg
Administration:	Oral administration; daily; for 14 days
Result:	Slightly alleviated alveolar bronchial fibrosis induced by NSC-125066.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley (SD) rats (aged 3-4 weeks) injected with NSC-125066
Dosage:	25 mg/kg
Administration:	Oral administration; daily; for 14 days
Result:	Slightly alleviated alveolar bronchial fibrosis induced by NSC-125066.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 31 mg/mL (60.90 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9645 mL	9.8224 mL	19.6448 mL
5 mM	0.3929 mL	1.9645 mL	3.9290 mL
10 mM	0.1964 mL	0.9822 mL	1.9645 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (4.91 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.91 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.91 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.91 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。